Mereo BioPharma (MREO) Asset Utilization Ratio (2024 - 2025)

Mereo BioPharma (MREO) posted quarterly Asset Utilization Ratio of 0.01 for Q4 2025, up 16.79% on a QoQ basis from 0.01 in Q3 2025.

Mereo BioPharma (MREO) Asset Utilization Ratio (2024 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported Asset Utilization Ratio for 2 consecutive years, with 0.01 the latest figure, recorded in Q4 2025.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.01 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01 (changed N/A YoY) and the FY2025 annual result came in at 0.01, changed N/A from the prior year.
Asset Utilization Ratio grew to 0.01 in Q4 2025 per MREO's latest filing, from 0.01 in the prior quarter.
Over the last five years, Asset Utilization Ratio for MREO reached as high as 0.16 in Q1 2024 and fell as low as 0.01 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Mereo BioPharma	232.52 Mn	232.52 Mn	-	-

Download Data